Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Active not recruiting 4

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1

Interventions

Carboplatin 109pembrolizumab 93Pemetrexed 83Cisplatin 67Specimen Handling 41durvalumab 36Paclitaxel 36Nivolumab 33Docetaxel 33atezolizumab 30Magnetic Resonance Spectroscopy 30osimertinib 29Radiotherapy 21Gemcitabine 21Etoposide 21130-nm albumin-bound paclitaxel 19Cetuximab 17amivantamab 14Radiosurgery 13Radiation 12Platinum 12Bevacizumab 12lazertinib 11cemiplimab 11Taxes 11Immunoglobulin G 11Topotecan 10Ipilimumab 10Drug Therapy 10Disulfides 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
berzosertib × Thoracic × 30 days × Clear all
NCT03896503 2026-06-01

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

National Cancer Institute (NCI)

Phase 2 Active not recruiting
104 enrolled 22 charts
Thoracic

Small Cell Lung Carcinoma

NCT04826341 2026-05-29

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
35 enrolled
Other solid neoplasmThoracic

HRD Cancer

NCT04216316 2026-05-28

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
12 enrolled 25 charts
Thoracic

Lung Neoplasms

NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡